
Fund Twenty8™

PORTFOLIO

The logo for SYNDICATE ROOM features a stylized bracket icon on the left, followed by the words "SYNDICATE" and "ROOM" stacked vertically in a bold, sans-serif font.

SYNDICATE
ROOM

WELCOME TO THE

FIRST AND ONLY PASSIVE EIS FUND

FOR EARLY-STAGE INVESTING

DIVERSIFICATION

This is the concept at the very heart of Fund Twenty8: to build a broad portfolio of early-stage companies, helping manage early-stage risk through diversification while allowing you to take advantage of generous EIS tax reliefs.

While similar-sized funds normally invest in just a few companies, covering a limited number of sectors, Fund Twenty8 invests in a minimum of 28 investments per fund, per year, offering truly sector-agnostic diversification.

SMART MONEY

Nested within SyndicateRoom, the UK's premier equity investment platform, Fund Twenty8's algorithmic approach draws on data from the investment decisions of thousands of sophisticated and high-net-worth investors to determine which companies to back.

FUND STATISTICS

Fund Twenty8 – 2016/17 raised a total of £4.55m from 233 professional clients, each investing between £10,000 and £200,000. As an industry-first fund, we were unbelievably impressed with the level of support it received from investors and the industry alike.



FUND PORTFOLIO

Fund Twenty8's final portfolio is a testament to its mission: to deliver investors a large and diversified portfolio of at least 28 investments.

The final portfolio consists of 32 investments spanning ten sectors. It features 18 startups, 11 scale-ups and 3 growth companies.

As our portfolio grows and raises further capital, we look forward to seeing its companies succeed.

One among our portfolio has already secured an additional £4.5m in capital from a large institutional investor to further accelerate the growth of the business and your investment.


To find out more about Fund Twenty8, please visit our website www.syndicateroom.com.

EIS BENEFITS AND FUND STRUCTURE

- HMRC-approved fund: all investments made are carried back to the tax year the fund closes
- Income tax relief offered at 30% on up to £1m per tax year
- No capital gains tax on disposal of shares after 3 years
- Deferral of other capital gains up to the amount reinvested
- Combined income tax and loss reliefs of up to 61.5%
- 100% inheritance tax relief available if held for 2 years (Business Property Relief)

NOTE: The above EIS benefits are available on eligible investments made into qualifying companies by the Fund. Individual losses are not offset against other gains within the Fund. EIS-qualifying investments must be held for a minimum of 3 years to receive the full tax-relief benefits.

SECTOR BREAKDOWN



3% ENGINEERING & MANUFACTURING

DYMAG

TOTAL RAISED // £499,999
INVESTMENT BY FUND // £131,859
LEAD INVESTOR // Boundary Capital (Fund)
STAGE // Growth

Dymag designs and manufactures lightweight carbon composite car and motorcycle wheels for vehicle Original Equipment Manufacturers, racing and the aftermarket.

6% ENVIRONMENT & RENEWABLES

ALERT TECHNOLOGY

TOTAL RAISED // £1,000,395
INVESTMENT BY FUND // £153,563
LEAD INVESTOR // DPTI (FUND)
STAGE // Scale-up

Alert Technology has created a device capable of detecting and monitoring airborne asbestos fibres in real time.

USIO

TOTAL RAISED // £591,123
INVESTMENT BY FUND // £189,781
LEAD INVESTOR // Leandro Almeida (Business Angel)
STAGE // Startup

USIO is a new entrant to the UK domestic energy market, using artificial intelligence to provide a more personalised service to users.

16% MARKETPLACES & E-COMMERCE

PEKAMA

TOTAL RAISED // £598,743
INVESTMENT BY FUND // £153,654
LEAD INVESTOR // Rockspring (Family Office)
STAGE // Startup

A platform connecting IP firms globally to improve their workflow, and increase efficiency and profitability.

BIOTECHSPERT

TOTAL RAISED // £236,099
INVESTMENT BY FUND // 50,273
LEAD INVESTOR // Zack Feather (Business Angel)
STAGE // Startup

Biotechspert facilitates access to specialist technical, scientific and commercial expertise on a global scale.

STARSTOCK

TOTAL RAISED // £1,324,491
INVESTMENT BY FUND // £115,123
LEAD INVESTOR // Downing Ventures (Fund)
STAGE // Startup

An online B2B marketplace enabling pubs to buy directly from brand owners, removing the need for wholesalers.

MAKE IT SOCIAL

TOTAL RAISED // £505,069
INVESTMENT BY FUND // £148,962
LEAD INVESTOR // Rob Dobson (Business Angel)
STAGE // Startup

Make it Social enables organisations to socialise their checkouts and simplify the process of making group bookings.

CELAME

TOTAL RAISED // £748,489
INVESTMENT BY FUND // £86,022
LEAD INVESTOR // Alicia Salinas (Business Angel)
STAGE // Startup

Celame aims to improve transparency and accessibility in the legal sector, and enhance and improve performance for legal firms seeking new digital clients.

9% HEALTHCARE

EPATIENT NETWORK

TOTAL RAISED // £470,374
INVESTMENT BY FUND // £110,101
LEAD INVESTOR // Pam Garside (Business Angel)
STAGE // Startup

ePatient Network provides rare disease patients with up-to-date scientific information, community insights and medical research, and connects them with clinical trial opportunities through its Raremark platform.

EMOQUO

TOTAL RAISED // £740,535
INVESTMENT BY FUND // £155,943
LEAD INVESTOR // Novus Investments (Fund)
STAGE // Startup

Emoquo provides a confidential coaching app used by people at work to help them deal with the day-to-day issues and challenges they face.

DEM DX

TOTAL RAISED // £524,868
INVESTMENT BY FUND // £97,370
LEAD INVESTOR // HK Anchor (Fund)
STAGE // Scale-up

Dem Dx is a diagnostic support tool for medical professionals that augments clinical diagnoses and helps teach better diagnostic skills.

3% MEDIA & TELECOMMUNICATIONS

SUPAPASS

TOTAL RAISED // £653,805
INVESTMENT BY FUND // £155,009
LEAD INVESTOR // Derek Watts (Business Angel)
STAGE // Startup

SupaPass is a B2B entertainment app giving content owners their own paywalled subscription service, enabling them to market directly to their audience and monetise their content.

25% PHARMACEUTICALS & BIOTECHNOLOGY

PEPTINNOVATE

TOTAL RAISED // £2,808,923
INVESTMENT BY FUND // £153,790
LEAD INVESTOR // DPTI (Fund)
STAGE // Scale-up

A drug development company engaged in the research and development of innovative medicines to control and potentially cure immuno-inflammatory diseases.

DIGITAL THERAPEUTICS

TOTAL RAISED // £404,794
INVESTMENT BY FUND // £46,829
LEAD INVESTOR // Dr Damien Marmion (Business Angel)
STAGE // Startup

Digital Therapeutics aims to address the swelling cost of preventable chronic diseases using digital therapeutic interventions.

RE-VANA THERAPEUTICS

TOTAL RAISED // £1,104,593
INVESTMENT BY FUND // £155,077
LEAD INVESTOR // TechstartNI (Fund)
STAGE // Scale-up

Re-Vana Therapeutics is a life science spin-out from Queen's University Belfast. Led by an experienced team of entrepreneurs and scientists, it aims to change the way eye medicines are delivered and mitigate the rising tide of blindness worldwide.

CAMALLERGY

TOTAL RAISED // £814,967
INVESTMENT BY FUND // £155,855
LEAD INVESTOR // Jonathan Milner (Business Angel)
STAGE // Scale-up

Camallergy's mission is to develop life-changing treatments for people with food allergies. Its lead product treats peanut allergy, a serious and increasingly prevalent disease with no licensed treatment.

3% MEDTECH

MOMENTUM BIOSCIENCE

TOTAL RAISED // £1,643,200
INVESTMENT BY FUND // £145,600
LEAD INVESTOR // Longwall Venture Partners (Fund)
STAGE // Scale-up

A business developing a range of innovative diagnostic products to help combat antibiotic resistance and sepsis by providing early detection of the presence and absence of bloodstream infections.

METRION BIOSCIENCES

TOTAL RAISED // £464,600
INVESTMENT BY FUND // £168,350
LEAD INVESTOR // Dr Keith McCullagh (Business Angel)
STAGE // Scale-up

Metrion Biosciences is a pharmaceutical contract research organisation specialising in delivering high-quality ion channel drug discovery and safety profiling services to the life science industry.

REDECOL

TOTAL RAISED // £589,563
INVESTMENT BY FUND // £189,963
LEAD INVESTOR // Barbara Lead (Business Angel)
STAGE // Startup

Redecol is a medical device company focused on the development of an asthma-monitoring device to address the need for a new type of lung function test.

CAMBRIDGE NUTRACEUTICALS

TOTAL RAISED // £1,875,348
INVESTMENT BY FUND // £189,872
LEAD INVESTOR // Peter Keen (Business Angel)
STAGE // Growth

Cambridge Nutraceuticals develops and markets health supplements which have been clinically proven to be effective and bioavailable.

ARCIS BIOTECHNOLOGY

TOTAL RAISED // £1,077,552
INVESTMENT BY FUND // £43,953
LEAD INVESTOR // Andrew Parker (Business Angel)
STAGE // Scale-up

Arcis Biotechnology is a research-led company with expertise in the development and commercialisation of a wide range of fast and convenient sample-preparation technologies.

22% SOFTWARE & COMPUTER SERVICES

WARWICK ANALYTICS

TOTAL RAISED // £495,878
INVESTMENT BY FUND // £105,596
LEAD INVESTOR // Robin Southwell OBE (Business Angel)
STAGE // Scale-up

Warwick Analytics' software allows companies to automate and semi-automate the time-consuming, manual processes involved in data preparation for predictive analytics.

BRYTLYT

TOTAL RAISED // £509,800
INVESTMENT BY FUND // £182,000
LEAD INVESTOR // Charles Morgan (Business Angel)
STAGE // Scale-up

Led by industry veteran Richard Heyns, Brytlyt fundamentally shifts the speed and cost of data processing by introducing a radically new approach to underlying hardware.

10T08

TOTAL RAISED // £588,950
INVESTMENT BY FUND // £124,124
LEAD INVESTOR // Anthony Jenkins (Business Angel)
STAGE // Startup

All-in-one appointment scheduling software that's already being used by over 2,000 companies in more than 30 countries and has facilitated over 1.58 million appointments.

TENDERSPACE

TOTAL RAISED // £482,985
INVESTMENT BY FUND // £189,109
LEAD INVESTOR // Ashley Tatham (Business Angel)
STAGE // Startup

TenderSpace is a collaborative platform for the construction industry that brings together projects, people and products.

ARTICHECK

TOTAL RAISED // £618,571
INVESTMENT BY FUND // £154,700
LEAD INVESTOR // Sir David Verey (Business Angel)
STAGE // Startup

Articheck is a SaaS business that creates passports for works of art to accompany them on their travels.

FANTOO

TOTAL RAISED // £585,838
INVESTMENT BY FUND // £42,041
LEAD INVESTOR // Martin Charmoy (Business Angel)
STAGE // Startup

A platform surfacing relevant business data and enabling people to plan their day and maximise their work output.

CYANCE

TOTAL RAISED // £549,996
INVESTMENT BY FUND // £185,640
LEAD INVESTOR // Peter Brooks (Business Angel)
STAGE // Startup

Cyance provides predictive marketing SaaS products, together with regulatory-compliant international data solutions and services.

9% TECHNOLOGY, HARDWARE & EQUIPMENT

WARWICK AUDIO TECHNOLOGIES

TOTAL RAISED // £2,131,030
INVESTMENT BY FUND // £155,999
LEAD INVESTOR // Mercia Technologies (Fund)
STAGE // Scale-up

Warwick Audio Technologies has created and patented a new type of electrostatic loudspeaker technology with which it's hoping to revolutionise the in-car audio experience.

SHIELDS ENERGY SERVICES

TOTAL RAISED // £899,133
INVESTMENT BY FUND // £189,990
LEAD INVESTOR // Michael Sofaer (Business Angel)
STAGE // Startup

Shields has developed a solution to enable energy users and utilities alike to monitor, analyse and control building energy use more intelligently, and eliminate energy waste in this rapidly evolving energy era.

FREEDOM ONE LIFE

TOTAL RAISED // £282,013
INVESTMENT BY FUND // £98,517
LEAD INVESTOR // Ian Marchant (Business Angel)
STAGE // Startup

Freedom One Life is developing a new generation of wheelchairs to empower those with physical disabilities to lead more independent, adventurous lives.

3% TRANSPORT & LOGISTICS

ENGENIE

TOTAL RAISED // £1,471,365
INVESTMENT BY FUND // £143,325
LEAD INVESTOR // Chris Dougan (Business Angel)
STAGE // Growth

Engenie is an electric-vehicle charging business focused on providing high-power rapid-charging facilities for electric cars and buses, catering both to consumers and commercial fleet and taxi operators.



The Pitt Building, Trumpington Street
Cambridge CB2 1RP
www.syndicatoroom.com
[@SyndicateRoom](https://twitter.com/SyndicateRoom)

IMPORTANT NOTICE

The information in this document is incomplete, and is subject to updates, revision, verification and amendment. This document does not constitute, or form part of, any offer to subscribe to the Fund, nor shall it (or any part of it) or the fact of its distribution form the basis of, or be relied upon in connection with, or act as any inducement to enter into, any contract or commitment whatsoever. Recipients of this document who are considering subscribing into the Fund are reminded that any such subscription must be made only on the basis of the information contained in the formal offering document relating to the Fund, which may be different from the information contained in this document.

Investing in early-stage businesses involves risks, including illiquidity, lack of dividends, loss of investment and dilution, and it should be done only as part of a diversified portfolio. SyndicateRoom is targeted exclusively at sophisticated investors who understand these risks and make their own investment decisions.

Tax relief depends on an individual's circumstances and may change in the future. In addition, the availability of tax relief depends on the company invested in maintaining its qualifying status.

Past performance is not a reliable indicator of future performance. You should not rely on any past performance as a guarantee of future investment performance.

Issued and approved by Syndicate Room Ltd, which is authorised and regulated by the Financial Conduct Authority (No. 613021) registered in England and Wales (No. 07697935) and has its Registered Office at The Pitt Building, Trumpington Street, Cambridge CB2 1RP. Please be aware that your capital is at risk and that your investment may go down as well as up in value.